Indra Mani Sharma Email and Phone Number

1. Spearheaded development of multiple mRNA QC assays2. SME in NGS based methods such as Illumina, PacBio, and Nanopore sequencing 3. Vital contribution in influencing Go or No Go decisions of the leadership

■ Devised strategy to investigate non-functional RNA decay in human cells.■ Discovered the role of pseudouridylation in RNA stability.■ Led generation of human cell lines using CRISPR-Cas9 and lentivirus approach.■ Defined cell sorting protocols using FACS to isolate gene-edited clonal populations.■ Designed and used siRNA, shRNA, ASO, LNA, and plasmid transfection.■ Optimized RT-PCR-based RNA analysis and quantifications.■ Led library preparation and execution of Illumina and nanopore sequencing.■ Led polysome and ribosome profiling based discoveries.■ Investigated ribosome collision in human cells.

■ Discovered first ever involvement of initiation factor 3 (IF3) in facilitating transition between ribosome biogenesis and translation initiation.■ Discovered a critical folding step in bacterial ribosomal RNA using RNA probing methods (SHAPE).■ Developed easy and fast protocol for large-scale purification of difficult-to-isolate RNA-protein complexes.■ Optimized label-free quantification of individual proteins in a mixture of proteins using LC-MS/MS.■ Optimized antibody-based RNA-protein complex pull down.■ Optimized fluorescence labeling and purification of >10 different nucleic acids and proteins.■ Developed an alternative method to the Northern blot to identify and quantify RNA species.

■ Devised strategy and executed purification, labeling, and characterization of fluorescent small circular dinucleotide RNA molecules. The company Biolog.de adopted my strategy to make this molecule for commercial purposes.■ Studied folding of small RNA dinucleotide.■ Extensive use of MALDI-TOF and LC-MS/MS to characterize small molecules and proteins.